ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2469

Diversity of Poly-Functional T Cells in Psoriatic Arthritis and Rheumatoid Arthritis and Its Therapeutic Significance

Siba Raychaudhuri1 and Smritikana Raychaudhuri 2, 1UC Davis School of Medicine, Sacramento, CA, 2UC Davis School of Medicine, Davis, CA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: polyfunctional T cells, psoriatic arthritis and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Importance to specific T cell subpopulations has been attributed for specific diseases such as Th17 cells in psoriatic disease, Th1 cells in TB and Th2 response for intracellular parasite infections. However, there are evidences that immune response is not a watertight condition for a specific T cell sub population.  As a clinician, we notice this diversity too; a patient of psoriatic arthritis (PsA) may respond to an anti-TNF agent whereas anti-IL-17A may not work; a patient may respond to anti-IL-23 but fails anti-IL-17A or anti-TNF agents. Considering this background here we have addressed poly-functionality of the activated effector memory T cells as well the difference of poly functionality in T cells between individual autoimmune disease such as in PsA and rheumatoid arthritis (RA).  

Methods: Peripheral blood (PBMC) synovial fluid (SFMC) mononuclear cells were collected from untreated PsA and RA (n=15/each) patients with active disease. Magnetically sorted CD3+ T cells were isolated from PBMCs and SFMCs; were activated (106 cells/ml) with anti-human CD3/CD28 cocktail and cultured in RPMI medium for 5 days (Fig 1).  Hi-D FACS studies were performed to: (i) identify activated memory cells (CD3+CD4+CD45RO+) T cells (ii) identify the percentage of following Th1/Th17 cytokine profile: IL-17A, IL-22, TNFα, IFNy.  The percentages of each cell population and the mean fluorescence intensity (MFI) were analyzed using Flow Jo software.  

Results: We noticed a marked polyfunctionality in PBMC/SFMC T cells both in PsA and RA. SFMC T-cells exhibited greater cytokine polyfunctionality, compared with matched blood. In PsA SFMCs the number of IL-17A (7.5+0.4%), IL-22(6.4+0.3%) and IL-23R (6.5+0.%) secreting cells were significantly higher than the PsA PBMCs (3.8+0.3%, 1.1+0.5%, 1.2+0.7%, respectively; p< 0.001).  Whereas % of TNFα T cells in PsA PBMCs (20.7+0.66) was higher than PsA SFMCs (8.16+0.11, p< 0.001); IFNy expressing cells in PBMCs and SFMCs were similar. RA SFMCs had significantly higher numbers of IL-17A (4.9+0.2%), IL-22 (2.5+0.1%), IL-23R (2.1+0.4%) and IFNy (24.3+0.2%) compared to RA PBMCs (1.8+0.%%, 0.8+0.2%, 1.0+0.5%, and 14.7+0.%% respectively, p< 0.001). RA PBMCs had higher numbers of TNFα secreting cells than RA SFMCs (15.8+0.5% vs 7.9+0.2%; p< 0.001).

Conclusion: Consistent to our and other reports we noticed activated CD4 memory T cells were the major source for these cytokines. Compared to RA (Fig 1), in PsA SFMCs significantly higher levels of IL-17A, IL-22 and IL-23R were noticed. In RA SFMCs the levels of TNFα and IFNγ were significantly higher- a trend towards a Th1 pattern.  The study supports the common view that in PsA the T cells are more skewed towards Th17 cells. Probably that explains better efficacy for anti-IL-17A targeted therapy in PsA compared to RA. More intriguing result is that in both in PsA and RA the pathological T cells in the SF were vastly polyfunctional. It is expected the kinetics of the polyfunctionality and thus their cytokine profile would vary at different time point of the disease and this could be one possible explanation for variations for responsiveness or failure to a specific anti-cytokine therapy.

Fig 1. Poly-Functional synovial fluid mononuclear -SFMC- T cells and its variance in psoriatic arthritis -PsA- and rheumatoid arthritis -RA-.


Disclosure: S. Raychaudhuri, AbbVie, 2, Amgen, 5, Janssen, 2, 5, Lilly, 5, Novartis, 2, 5, Pfizer, 2, 5, Pfizer Inc, 2, Sun Pharma, 2; S. Raychaudhuri, Sun Pharmaceutical Industries Limited, 2.

To cite this abstract in AMA style:

Raychaudhuri S, Raychaudhuri S. Diversity of Poly-Functional T Cells in Psoriatic Arthritis and Rheumatoid Arthritis and Its Therapeutic Significance [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/diversity-of-poly-functional-t-cells-in-psoriatic-arthritis-and-rheumatoid-arthritis-and-its-therapeutic-significance/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/diversity-of-poly-functional-t-cells-in-psoriatic-arthritis-and-rheumatoid-arthritis-and-its-therapeutic-significance/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology